A*STAR Bioinformatics Institute (A*STAR BII)

Researchers discover a protein-cutting enzyme that may be responsible for inflammatory skin conditions triggered by yeast species.

In a breakthrough study, researchers identify how an enzyme found in fungi produces a natural chemical commonly used in cosmetics, fragrances and medicines.

While the new Omicron XBB COVID-19 subvariant deftly dodges immune defences even in vaccinated individuals, researchers find that mixed mRNA vaccines may offer a vital boost of protection.

From molecular methods to advanced optics, scientists are combining techniques and expertise from diverse disciplines to transform skin health research and fortify the body’s outermost barrier.

Through close collaborations across scientific disciplines, A*STAR drives new discoveries in neurometabolism and its potential therapeutic applications.

Researchers develop a protocol to boost the effectiveness of and reduce the risk of potential side effects for T cell cancer therapies.

By exploring the genetic diversity within Escherichia coli bacteria, researchers uncover distinct gene families and a molecular weapon tied to disease-causing strains.

Researchers identify an unexpected synergy between bacterial and viral molecules that causes severe inflammation in some patients with COVID-19.

Inactivated COVID-19 vaccines could be an equally potent alternative for people with allergic sensitivities to mRNA-based vaccines.

As Sir David and Birgit Lane leave Singapore, A*STAR Research commemorates the legacy that the couple continues to build for their students, colleagues and the nation’s wider research ecosystem.

Leveraging on its public sector and industry collaborations, A*STAR and the Experimental Drug Development Centre hold the keys to effective drug discovery and development.

Researchers develop machine learning models for accurately diagnosing an inflammatory skin condition.